Merck, Schering backpedal on Vytorin

All right, already. Merck and Schering-Plough have responded to public outcry over their plans to re-jig a study of Vytorin, a joint product that combines Merck's Zocor and Schering-Plough's Zetia. The ENHANCE trial wrapped up last year, but results haven't been released. Here's the background: Funded by the two companies, ENHANCE compares Vytorin to Zocor alone. If Vytorin proves superior to the now-off-patent Zocor, doctors might prescribe the $3-per-day brand name drug instead of Zocor's generic competition.

Last month, Merck and Schering-Plough said they planned to change the study's primary endpoint. Previously, the trial was focusing on the drugs' ability to keep arteries clear in three different spots per patient; the companies wanted to change that to the carotid artery alone.

But last week, lawmakers demanded data from the companies about the clinical trial, saying they were concerned about the delay in results and about the "apparent manipulation of trial data." Now, the drug makers are back-pedaling; they'll stick to the original criteria.

- see the House Committee on Energy and Commerce letter
- read the UPI report
- check out the WSJ article about the study's lead investigator
- here's more background from the Star-Ledger

Related Article:
Sleep study could boost some statins. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.